Josh Peterson Archives
Study finds genetic screening of adults would be cost-effective
May. 9, 2023—A Vanderbilt analysis of population genetic testing concludes with a recommendation to U.S. health policymakers to adopt routine testing of adults ages 40 and under for three genetic conditions posing high risk of life-threatening illness.
PheWAS reveals post-COVID-19 diagnoses
Sep. 8, 2022—Using a high-throughput informatics technique and electronic health records, Vanderbilt researchers found that COVID-19 survivors had an increased risk for more than 40 new diagnoses.
Study explores clinical uses for polygenic risk scores
Jul. 14, 2022—Vanderbilt University Medical Center has received a five-year, $4.5 million grant from the National Human Genome Research Institute to assess clinical outcomes and economic value of screening large, diverse health care populations for disease risk using polygenic risk scores.
Study shows gene-drug interactions are common
Sep. 2, 2021—When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing.
Peterson tapped to direct VUMC’s Center for Precision Medicine
Nov. 18, 2020—Josh Peterson, MD, MPH, professor of Biomedical Informatics and Medicine, has been named director of the Center for Precision Medicine at Vanderbilt University Medical Center, effective since Oct. 1. The center is VUMC’s hub for interdisciplinary research in precision medicine. Housed within the Department of Biomedical Informatics, it was founded in 2015 by Joshua Denny,...
Screening younger women for hereditary cancers may be cost effective
Nov. 5, 2020—Population-wide screening for genetic variants linked to hereditary breast and ovarian cancer may be cost effective in women between the ages of 20 and 35, according to a study published in JAMA Network Open.
VUMC-led network to focus on polygenic risk for common diseases
Jul. 1, 2020—With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.
VUMC team creates COVID-19 research registry
Apr. 23, 2020—Out of the electronic health records (EHRs) of patients seen at Vanderbilt University Medical Center, a team in the Department of Biomedical Informatics is creating a COVID-19 patient registry as a platform for research.
Peterson, Roden honored for translational medicine efforts
Oct. 17, 2019—Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.
Study ‘ignites’ link between genes and drug response
Jul. 25, 2019—A national study is seeking to determine whether genetic testing can help physicians choose the best drugs for their patients to relieve pain and depression.
Personalized drug prescribing program expands, upgrades
Jan. 25, 2018—Vanderbilt University Medical Center (VUMC) has expanded and relaunched genetic testing to predict patient responses to drugs.
Study looks at doctors’ response to genetic testing
Mar. 31, 2016—A new clinical implementation study from Vanderbilt University Medical Center measures how physicians have responded to the introduction of routine genetic testing to predict patient response to the commonly prescribed antiplatelet drug clopidogrel.
